Immediate Evaluation and Management
Discontinue tirzepatide (Mounjaro) immediately and evaluate for acute pancreatitis with lipase measurement, clinical assessment, and CT imaging if lipase is >3× upper limit of normal or clinical suspicion is high. 1
Initial Diagnostic Approach
The FDA label explicitly warns that tirzepatide causes mean increases in pancreatic amylase (33-38%) and lipase (31-42%) even without pancreatitis 1. However, you must distinguish between drug-related enzyme elevation and true acute pancreatitis.
Key Diagnostic Criteria for Acute Pancreatitis
Based on established guidelines, acute pancreatitis requires 2:
- Compatible clinical features (persistent severe abdominal pain, often radiating to back, ±vomiting)
- Enzyme elevation >3× upper limit of normal for diagnosis
- Lipase is preferred over amylase (higher specificity)
- Elevations <3× ULN have low specificity and are "consistent with but not diagnostic of" pancreatitis
- CT confirmation if diagnosis unclear (wait 72 hours from symptom onset for accurate assessment of necrosis)
Critical Decision Point: Is This Pancreatitis?
If amylase/lipase >3× ULN with compatible pain: Presume acute pancreatitis and proceed with full evaluation 2
If amylase/lipase <3× ULN: This may represent:
- Drug-induced enzyme elevation without pancreatitis (common with tirzepatide) 1
- Early/evolving pancreatitis
- Alternative diagnosis (gastroenteritis, biliary colic, etc.)
Medication Management
Tirzepatide (Mounjaro)
Stop immediately 1. The FDA label states: "If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management." Case reports demonstrate temporal correlation between tirzepatide initiation and pancreatitis, with resolution upon discontinuation 3. While pancreatitis rates are low (≤1% in trials) 4, the drug causes consistent enzyme elevations and has documented cases of severe pancreatitis with lipase >11,000 U/L 3.
SGLT-2 Inhibitor
Continue the SGLT-2 inhibitor unless severe illness develops. The primary concern with SGLT-2 inhibitors is euglycemic ketoacidosis, not pancreatitis 5. While one study found SGLT-2 inhibitors associated with acute pancreatitis 6, this is far less established than with GLP-1 agonists.
Monitor for ketoacidosis risk factors 5:
- Check beta-hydroxybutyrate and glucose
- Ensure adequate hydration (SGLT-2 inhibitors cause osmotic diuresis)
- Consider glucose-containing IV fluids if prolonged fasting required
- Watch for high anion gap acidosis
Stop SGLT-2 inhibitor only if:
- Patient develops ketoacidosis (ketones >3.0 mmol/L, pH <7.3)
- Severe dehydration/acute kidney injury develops
- Patient requires surgery/prolonged NPO status 5
Severity Assessment and Triage
Evaluate for severe pancreatitis using 2:
- APACHE II score (preferred; cutoff ≥8 indicates severe disease)
- Organ failure (most predictive of mortality)
- Persistent symptoms beyond 48 hours
If APACHE II >8 or organ failure present: Transfer to ICU/intermediate care unit 2
If predicted severe disease: Obtain contrast-enhanced CT after 72 hours to assess for pancreatic necrosis 2
Supportive Management
- NPO status with IV hydration
- Aggressive fluid resuscitation (especially important given SGLT-2 inhibitor on board)
- Pain control
- Monitor renal function closely (both drugs can contribute to volume depletion) 1
- Serial enzyme measurements to track trajectory
Common Pitfalls
Assuming all enzyme elevations = pancreatitis: Tirzepatide routinely causes 30-40% enzyme increases without pancreatitis 1. Use the 3× ULN threshold and clinical correlation 2.
Stopping SGLT-2 inhibitor unnecessarily: Unless ketoacidosis or severe illness develops, continuing the SGLT-2 inhibitor may benefit cardiovascular/renal outcomes 5.
Missing euglycemic ketoacidosis: Check ketones even with normal glucose in SGLT-2 inhibitor users with abdominal pain 5.
Early CT imaging: If CT needed, wait 72 hours from symptom onset for accurate necrosis assessment 2.
Restarting tirzepatide: Do not rechallenge with tirzepatide if pancreatitis confirmed 1.
Alternative Diagnoses to Consider
Given "acute food intolerance" history:
- Gastroenteritis (most likely if enzymes <3× ULN)
- Biliary colic (check RUQ ultrasound)
- Peptic ulcer disease
- Bowel obstruction (tirzepatide delays gastric emptying) 1